KR20180042795A - Composition for enhancing cognitive function comprising novel quercetin-based compound - Google Patents

Abstract

The present specification relates to a composition for treating the cognitive function decrease comprising a novel quercetin-based compound isolated from post-fermented tea, an isomer thereof, pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The composition can be widely utilized in the fields related to cognitive function and nerve cell protection.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for improving cognitive function comprising a novel quercetin-based compound,

TECHNICAL FIELD The present invention relates to a composition for improving cognitive function comprising a novel quercetin-based compound.

As the level of living and the development of the medical industry enabled the treatment of intractable diseases such as cancer, life span of human increased, but the aging of the population caused deterioration of cognitive function and increase of chronic degenerative neurology, The quality of the relatively low. Neuronal dysfunction and damage can be caused by specific proteins that are susceptible to aggregation, and many neurological diseases are characterized by such conditions. Such neurological diseases include diseases such as Alzheimer's disease.

As the elderly population increases, there is a growing need for the treatment and prevention of aging, cognitive dysfunction, degenerative neurological diseases and brain diseases, and studies on prevention, treatment, mitigation and improvement of such aging and diseases are steadily However, existing drugs have problems such as unclear effects or side effects, so it is necessary to develop therapeutic agents derived from natural materials to solve such problems.

Green tea is used as a green tea leaf form or as a fermented tea to feel a deeper flavor. Fermented green tea means that the green tea leaves have been oxidized, and includes fermented tea which is oxidized by an oxidizing enzyme present in tea leaves, fermented tea after fermentation by a separate microorganism other than an enzyme present in tea leaves . Depending on the degree of fermentation, it can be classified into a fermented tea, a semi-fermented tea, and a fully fermented tea. For example, fermented green tea is referred to as various names such as green tea, oolong tea, black tea, and vivid tea depending on the type and degree of fermentation.

The difference in fermentation state shows differences in flavor as compared with that of green tea, and can show a large difference in kind and content of active ingredients depending on the specific fermentation process and the type of microorganism. Since various compounds can be generated and separated as described above, various efforts for isolating and identifying unknown compounds using green tea are continuing.

Korean Patent Registration No. 10-0975199

In one aspect, the present invention aims to discover a novel quercetin-based compound derived from a post fermentation tea and to use it for improving cognitive function and protecting nerve cells.

There is provided a composition for improving the lowering of cognitive function comprising a compound of the following formula 1, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, or a post fermented tea extract containing the same as an active ingredient.

[Chemical Formula 1]

Wherein R ₁ is C ₁₅ H ₉ O ₇ , R ₂ is H or C ₆ H ₁₁ O ₅ , and R ₃ is C ₉ H ₇ O ₂ Lt; / RTI >

In another aspect, the present invention provides a composition for protecting a nerve cell comprising the compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, or a post fermented tea extract containing the same as an active ingredient do.

In one aspect of the present invention, a novel compound isolated from a post-fermentation tea can be used in a cognitive function improvement field and a nerve cell protection field, thereby being widely used in a post-fermentation tea industry, a cognitive function field, have.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the activity of quercetin 3-O- [3-O "- (E) - p-coumaroyl] [β-D-glucopyranosyl- (1 → 3) -O- 1? 6) -O-? -D-glucopyranoside].
FIG. 2 is a graph showing the activity of quercetin 3-O- [3-O "- (E) - p-coumaroyl] [β-D-glucopyranosyl- (1 → 3) -O- 1? 6) -O-? -D-glucopyranoside] of the present invention is a ¹ H-NMR (nuclear magnetic resonance) spectrum.
Figure 3 is a graph showing the activity of quercetin 3-O- [3-O- (E) - p-coumaroyl] [beta] -D-glucopyranosyl- (1 → 3) -O- 1 → 6) -O-β- D- gluconic shows the ¹³ C-NMR spectrum of the nose Llano side.
Figure 4 is a graph showing the activity of quercetin 3-O- [3-O- (E) - p-coumaroyl] [beta] -D-glucopyranosyl- (1 → 3) -O- 1? 6) -O-? -D-glucopyranoside]. FIG. 2 shows the ¹ H- ¹³ C HSQC (Heteronuclear Single Quantum Coherence) spectrum.
FIG. 5 is a graph showing the activity of quercetin 3-O- [3-O "- (E) - p-coumaroyl] [β-D-glucopyranosyl- (1 → 3) -O- ^{1 → 6) 1 H- 13 C} Heteronuclear Multiple-Bond Coherence (HMBC the -O-β-D- gluconic nose Llano side]) shows the spectrum.
Figure 6 is a graph showing the activity of quercetin 3-O- [3-O- (E) - p-coumaroyl] [[alpha] -L-rhamnopyranosyl- (1 → 6) -O- beta -D- glucopyranoside] ≪ / RTI >
Figure 7 is a graph showing the activity of quercetin 3-O- [3-O- (E) - p-coumaroyl] [[alpha] -L-rhamnopyranosyl- (1-6) -O- ≪ ¹ > H-NMR spectrum.
Figure 8 is a graph showing the activity of quercetin 3-O- [3-O- (E) -p-cumaroyl] [[alpha] -L-rhamnopyranosyl- (1-6) -O- ≪ ¹³ > C-NMR spectrum.
Figure 9 is a graph showing the activity of quercetin 3-O- [3-O- (E) - p-coumaroyl] [[alpha] -L-rhamnopyranosyl- (1-6) -O- beta -D- glucopyranoside] ¹ H- ¹³ C HSQC (Heteronuclear Single Quantum Coherence) spectrum.
Figure 10 is a graph showing the activity of quercetin 3-O- [3-O "- (E) -p-cumaroyl] [[alpha] -L-Raminopyranosyl- (1 → 6) -O- ¹ H- ¹³ C HMBC (Heteronuclear Multiple-Bond Coherence) spectrum.
Figure 11 shows the effect of the compound according to one aspect of the present invention on the aggregation of beta amyloid.

Hereinafter, the present invention will be described in detail.

Herein, " post-fermentation " includes fermentation by a separate microorganism or substance other than enzymes present in tea leaves. The post-fermentation tea contains the fermented green tea by the above-mentioned method.

As used herein, the term "extract" refers to a substance obtained by extracting a component contained therein from a natural product, regardless of the method of extraction or the kind of the component. For example, a substance obtained by extracting a component dissolved in a solvent from a natural product using water or an organic solvent, a product obtained by extracting only a specific component such as oil, a specific component of a natural product, And one fraction.

As used herein, the term " fraction " includes fractions or fractions of a particular substance or extract using any solvent, and re-extraction thereof with a particular solvent. The fractionation method and the extraction method may be any method known to those of ordinary skill in the art.

As used herein, the term "isomers" refers in particular to optical isomers (for example, essentially pure enantiomers, essentially pure diastereomers or mixtures thereof) as well as morphological isomers (i. e., isomers differing only in the angle of one or more chemical bonds), position isomers (especially tautomers) or geometric isomers (e.g., cis-trans isomers) do.

As used herein, "essentially pure ", when used in reference to an enantiomer or partial isomer, means that at least about 90%, preferably at least about 95%, of a specific compound, such as an enantiomer or partial isomer, , More preferably at least about 97% or at least about 98%, even more preferably at least about 99%, even more preferably at least about 99.5% (w / w).

As used herein, the term " pharmaceutically acceptable "is intended to refer to the approval of a government or equivalent regulatory agency that can be used on animals, and more specifically on humans, by avoiding significant toxic effects when used in conventional medicinal dosages. Received, approved, or listed in a pharmacopeia or described in other general pharmacopoeias.

As used herein, "pharmaceutically acceptable salt" means a salt according to one aspect of the present invention which is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. The salt may be (1) formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; (3-hydroxybenzoyl) benzoic acid, or an acetic acid, propionic acid, hexanoic acid, cyclopentenepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4- chlorobenzenesulfonic acid, 2- 4-methylbicyclo [2,2,2] -oct-2-en-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert Acid addition salts formed with organic acids such as butylacetic acid, laurylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid; Or (2) salts formed when the acidic proton present in the parent compound is substituted.

As used herein, " hydrate " means a compound to which water is bound, and is a broad concept that includes an inclusion compound having no chemical bonding force between water and the compound.

As used herein, " solvate " means a higher order compound formed between a molecule or ion of a solute and a molecule or ion of a solvent.

In one aspect, the present invention provides a method for improving cognitive function deterioration comprising, as an active ingredient, a compound of the following formula 1, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, Lt; / RTI >

[Chemical Formula 1]

In the above formula (1), R ₁ is C ₁₅ H ₉ O ₇ , R ₂ is H or C ₆ H ₁₁ O ₅ , and R ₃ is C ₉ H ₇ O ₂ .

According to one embodiment, R < ₁ > may be a compound of the following formula (2).

(2)

According to another embodiment, R < ₂ > may be a compound of formula (3).

(3)

And R < ₃ >

[Chemical Formula 4]

According to another embodiment, the compound is selected from the group consisting of quercetin 3-O- [3-O "- (E) -p-coumaroyl] [β-D-glucopyranosyl- (1? 6) -O-? -D-glucopyranoside] (Quercetin3-O- [3-O "- (E) -p- coumaroyl] [? - D- glucopyranosyl- - (3) -O- [alpha] -L-rhamnopyranosyl- (1-6) -O- [beta] -D- glucopyranoside. (1 → 6) -O- β-D-glucopyranoside] is a compound represented by the following general formula (5): [β-D-glucopyranosyl- (1 → 3) -O- α-L -laminopyranosyl- Can be displayed.

[Chemical Formula 5]

According to another embodiment, the compound is selected from the group consisting of quercetin 3-O- [3-O "- (E) -p-coumaroyl] [α-L-rhamnopyranosyl- -β-D-glucopyranoside] (Quercetin 3-O- [3-O "- (E) -p-coumaroyl] [α-L-rhamnopyranosyl- (1 → 6) -O- [beta] -D-glucopyranosyl- [alpha] -L-rhamnopyranosyl- (1 → 6) -O- [3- Side] can be represented by the following formula (6).

[Chemical Formula 6]

According to an aspect of the present invention, the method for producing the compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof may include synthesis, isolation from natural products, and the like.

According to another embodiment, said post-fermentation may be by inoculation with a strain, said strain being selected from the group consisting of Saccharomyces sp., Bacillus sp., Lactobacillus sp. Stock in (Leuconostoc mesenteroides sp.) that can be a strain, preferably a Saccharomyces as MY process three Levy jiae (Saccharomyces cerevisiae) selected from, Lactobacillus Kasei (Lactobacillus casei), Bacillus subtilis (Bacillus subtlis), Lactobacillus Lactobacillus bulgarius and Leuconostoc mesenteroides ). According to another embodiment, the post-fermentation tea may be a post-fermented green tea.

In one aspect, the present invention provides a compound of the present invention, which has been discovered by the present inventors after a continuous study on post-fermentation tea. As a result of beta-amyloid aggregation assay using the above compounds, It has been confirmed that beta-amyloid aggregation inhibitory effect is superior to that of the inhibitors morin and phenol red. Accordingly, it has been found that the compounds according to one aspect of the present invention can be used to prevent, treat and ameliorate cognitive dysfunction associated with beta-amyloid, and also to prevent neuronal damage from damage and death due to beta-amyloid aggregation Lt; / RTI > (see FIG. 11).

Also, in one aspect of the invention, the compounds enhance BDNF expression and decrease DNMT1 expression in neurons. That is, the present invention can be effectively utilized for the prevention and treatment of neurodegenerative diseases such as dementia, dementia, Alzheimer's disease and the like, which are associated with a decrease in BDNF expression or an increase in DNMT1 expression.

In one embodiment, the extraction may be extraction with one or more solvents selected from hydrothermal, C ₁ to C ₆ lower alcohols, and mixed solvents thereof. According to other embodiments, the lower alcohols are May be used alone or in a mixture, preferably ethanol.

According to another aspect of the present invention, the extract may be a fraction which is fractionated into ketones after extraction.

According to another embodiment, the ketone is selected from the group consisting of acetone, carvone, pulegone, isolongifolanone, 2-heptanone, 2-pentanone, 3-hexanone, 3- , 2-octanone, 3-octanone, 2-nonanone, 3-nonanone, 2-undecanone, 2-tridecanone, methyl isopropyl ketone, ethyl isoamyl ketone, Aminocyclopentene, 2,3-heptanedione, 2,3-heptanedione, 2,3-heptanedione, 2,3-heptanedione, 2,3-heptanedione, 2-n-heptylcyclopentanone, cis-jasmone, dihydrojasmone, methylcorylon, 2-tert-butylcyclohexylcyclohexanone, Cyclohexanone, p-tert-butylcyclohexanone, 2-sec-butylcyclohexanone, celery ketone, krypton, p-tert- pentylcyclohexanone, methylcyclocitronone, 2-pentanone, oxide ketone, imicosporon, Methyl naphthyl ketone, alpha -methyl anisacetone, anisyl acetone, p-methoxyphenylacetone, benzylidene acetone, p-methoxyacetophenone, p-methylacetophenone, propiophenone, acetophenone, Dynascone, litorone, ionone, pseudoionone, methylionone, methylylitone, 2,4-di-tert-butylcyclohexanone, allylionone, 2 -Acetyl-3,3-dimethylnorbornane, verbenone, fenchone, cyclopentadecanone, cyclohexadecenone, and the like, and ketones as solvents which can be generally used in the art and their And mixtures thereof, preferably acetone.

According to an aspect of the present invention, the content of the compound of formula (I), its isomer, its pharmaceutically acceptable salt, its hydrate or a solvate thereof in the composition is 0.00001 wt% to 10 wt% . The content may be 0.00001 wt% or more, 0.00005 wt% or more, 0.0001 wt% or more, 0.0005 wt% or more, 0.001 wt% or more, 0.005 wt% or more, 0.01 wt% or more, % Or more, 0.5% or more, 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% % ≪ / RTI > by weight. Also included is an amount of up to 10 weight percent, up to 9 weight percent, up to 8 weight percent, up to 7 weight percent, up to 6 weight percent, up to 5 weight percent, up to 4 weight percent, up to 3 weight percent, up to 2 weight percent, , Not more than 0.5 wt%, not more than 0.1 wt%, not more than 0.05 wt%, not more than 0.01 wt%, not more than 0.005 wt%, not more than 0.001 wt%, not more than 0.0005 wt%, not more than 0.0001 wt% % ≪ / RTI >

According to another aspect of the present invention, the content of the post fermented tea extract in the composition may be 0.1 wt% to 90 wt% based on the total weight of the composition. The content is 0.1 wt% or more, 1 wt% or more, 5 wt% or more, 10 wt% or more, 15 wt% or more, 20 wt% or more, 25 wt% or more, 30 wt% or more, 35 wt% % Or more, 40 wt% or more, 45 wt% or more, 50 wt% or more, 55 wt% or more, 60 wt% or more, 65 wt% or more, 70 wt% or more, 75 wt% or more, 80 wt% % ≪ / RTI > by weight. Or less, 90 wt% or less, 85 wt% or less, 80 wt% or less, 75 wt% or less, 70 wt% or less, 65 wt% or less, 60 wt% or less, 55 wt% or less, 50 wt% Up to 40 weight percent, 35 weight percent or less, 30 weight percent or less, 25 weight percent or less, 20 weight percent or less, 15 weight percent or less, 10 weight percent or less, 5 weight percent or less, 1 weight percent or less, % ≪ / RTI >

According to another aspect of the present invention, there is provided a pharmaceutical composition comprising the compound of Formula 1, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof in an amount of 0.0001% by weight or more, At least 0.001 wt.%, At least 0.005 wt.%, At least 0.01 wt.%, At least 0.05 wt.%, At least 0.1 wt.%, At least 0.5 wt.%, At least 1 wt.%, At least 3 wt.%, At least 5 wt. %, 10 wt% or more, 12 wt% or more, 15 wt% or more, or 18 wt% or more. % Or less, 5 wt% or less, 3 wt% or less, 1 wt% or less, 0.5 wt% or less, 0.1 wt% or less, , Not more than 0.05% by weight, not more than 0.01% by weight, not more than 0.005% by weight, not more than 0.001% by weight, not more than 0.0005% by weight, or not more than 0.0003% by weight. Preferably, the extract may contain 0.0001% to 20% by weight of the compound of Formula 1, its isomer, its pharmaceutically acceptable salt, its hydrate, or its solvate, based on the total weight of the extract .

According to another aspect of the present invention, the dosage of the compound of Formula 1, its isomer, its pharmaceutically acceptable salt, its hydrate, or its solvate by administration of the composition is 0.001 mg / kg / 100 mg / kg / day. The dosage is in the range of 0.001 mg / kg per day, 0.005 mg / kg per day, 0.01 mg / kg per day, 0.05 mg / kg per day, 0.1 mg / kg per day, 0.5 mg / kg per day Day or more, 5 mg / kg / day, 10 mg / kg / day, 15 mg / kg / day, 20 mg / kg / day, 25 mg / kg / day or more and 30 mg / kg / day or more Kg / day, at least 40 mg / kg / day, at least 45 mg / kg / day, at least 50 mg / kg / day, at least 55 mg / kg / day, at least 60 mg / kg / day, at least 65 mg / Day, at least 7 mg / kg / day, at least 75 mg / kg / day, at least 80 mg / kg / day, at least 85 mg / kg / day, at least 90 mg / kg / day, or at least 95 mg / kg / day. Also, the dose is not more than 100 mg / kg / day, not more than 95 mg / kg / day, not more than 90 mg / kg / day, not more than 85 mg / kg / day, 65 mg / kg / day, 60 mg / kg / day, 55 mg / kg / day, 50 mg / kg / day, 45 mg / kg / day, 40 mg / Kg / day, up to 30 mg / kg / day, up to 25 mg / kg / day, up to 20 mg / kg / day, up to 15 mg / kg / day, up to 10 mg / Day, up to 0.5 mg / kg / day, up to 0.1 mg / kg / day, up to 0.05 mg / kg / day, up to 0.01 mg / kg / day, up to 0.005 mg / ≪ / RTI >

According to one embodiment, the cognitive decline is due to aggregation of β-amyloid, formation of beta amyloid plaque, or loss of brain-derived neurotrophic factor (BDNF) And increased expression of DNA (cytosine-5) -methyltransferase 1 (DNMT1).

According to another embodiment, the cognitive function lowering may include at least one selected from the group consisting of memory loss, cognitive decline, discrimination decline, depression, and forgetfulness.

According to another embodiment, the improvement is achieved by inhibiting the aggregation of beta-amyloid, inhibiting plaque formation of beta-amyloid, degrading beta-amyloid plaque or aggregated beta-amyloid, enhancing BDNF expression and decreasing DNMT1 expression It may be through one or more selected from the group.

According to one embodiment of the present invention, the composition may be a composition for protecting a nerve cell.

According to another embodiment, the neuronal cell protection may be to protect neurons from the effects of beta-amyloid aggregation or reduction of plaque, BDNF expression or DNMT1 expression enhancement. Since aggregated beta amyloid is known to damage and kill nerve cells, according to one aspect of the present invention, it is possible to protect nerve cells when inhibiting aggregation or plaque formation of beta amyloid. In addition, DNMT1 inhibits gene expression by causing DNA methylation, which leads to problems such as BDNF expression, resulting in decreased cognitive abilities. In one aspect, the present invention inhibits the activity of DNA methyltransferase 1 (DNMT1) to inhibit DNA methylation, thereby contributing to improvement of cognitive ability and neurodegenerative diseases through protection of nerve cells.

According to another aspect of the present invention, the composition may be a pharmaceutical composition or a food composition. In one aspect, the composition may be a pharmaceutical composition for preventing or treating neurodegenerative diseases. In another aspect, the neurodegenerative disease may be caused by one or more selected from the group consisting of aggregation of beta amyloid, decreased BDNF expression, and increased expression of DNMT1. In another aspect, the neurodegenerative diseases include dementia, Alzheimer ' s disease, amnesia, and the like.

The pharmaceutical composition according to one aspect of the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like. Formulations for oral administration may be in the form of tablets, pills, soft and hard capsules, granules, powders, granules, solutions, emulsions or pellets, It is not. Formulations for parenteral administration may be, but are not limited to, solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches or spray formers. The formulations may be readily prepared according to conventional methods in the art and may be prepared by conventional means including, but not limited to, surfactants, excipients, wetting agents, emulsifying accelerators, suspending agents, salts or buffers for controlling osmotic pressure, colorants, spices, stabilizers, preservatives, Other adjuvants may also be included.

The amount or dosage of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathological condition and severity of the subject to be treated, the administration route or the judgment of the prescriber. Determination of the amount of application based on these factors is within the level of those skilled in the art.

The formulation of the food composition is not particularly limited and may be formulated into, for example, tablets, granules, pills, powders, liquid preparations such as drinks, caramels, gels, bars, tea bags and the like. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.

The composition may be administered by various methods such as simple ingestion, drinking, injection administration, spray administration or squeeze administration.

In the food composition according to one aspect of the present invention, the determination of the dosage of the active ingredient is within the level of those skilled in the art, and may vary depending on various factors such as the age, health condition, and complication of the subject.

The food composition according to one aspect of the present invention can be applied to any type of processed food such as various food products such as chewing gum, caramel product, candy, ice cream, confectionery, soft drink, mineral water, And may be a health functional foodstuff including vitamins and minerals.

In addition to the above, the food composition according to one aspect of the present invention may be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and enhancers (cheese, Salts of alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the food compositions according to one aspect of the present invention may include natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally comprised in the range of 0 to about 50 parts by weight per 100 parts by weight of the composition according to one aspect of the present invention.

Hereinafter, the configuration and effect of the present invention will be described in more detail with reference to examples, experimental examples, and formulation examples. However, these examples are provided for illustrative purposes only in order to facilitate understanding of the present specification, and the scope and range of the present specification are not limited by the following examples.

[Example 1] Preparation of post-fermentation tea samples

Water was added to green tea made from green tea ( Camellia sinensis var. Yabukita ) leaf to adjust the moisture content to 40% by weight. Bacillus subtillis (5 × 10 ⁶ cfu / g) was inoculated therein, fermented at 50 ° C. for 3 days, and fermented at 80 ° C. for 4 days.

The aged tea samples were pulverized for 15 seconds, and then sieved with a stainless steel sieve having a mesh size of 1 mm. Then, 50 mg of the pulverized product was added to a 1.5 ml Eppendorf tube, and 1 ml of deionized water was added thereto. The mixture was stirred at a constant rate for 30 minutes in a constant temperature water bath at 60 ° C, and centrifuged at 25,000C for 13 minutes at 13,000 rpm. Only the non - soluble portion of the dried fermented green tea extract was isolated.

[Example 2] Fractionation and compound separation

150 g of the post-fermentation tea sample was fractionated with acetone to remove catechin derivatives and caffeine, and a solubilized product in which other compounds were concentrated. 40 g of the acetone solubles were first fractionated by silica gel column chromatography using a 5: 1 (v / v) mixture of chloroform: methanol as a solvent.

8.9 g of the caffeine-free chloroform: methanol 5: 1 (v / v) fraction was fractionated using high-performance countercurrent chromatography (HPCCC, Dynamic Extractions Ltd, UK). The solvent used was n-hexane-TBME (Methyl tert-butyl ether) -BuOH-MeCN-Water (0.25: 3: 1: 1: 5, v / v) and the flow rate was 25 ml / min. A total of 10 sub-fractions were divided using the above conditions and each fraction was further purified with a small volume HPCCC (Dynamic Extractions Ltd, UK), HPLC (High-performance liquid chromatography), SEPHADEX LH-20 column -Sciences, Sweden) were used to separate the components contained in each fraction.

As a result, it was confirmed that quercetin 3-O- [3-O "- (E) -p-coumaroyl] [β-D-glucopyranosyl- (1 → 3) -O (1? 6) -O-? -D-glucopyranoside] (Quercetin 3-O- [3-O "- (E) -p- coumaroyl] [? glucopyranosyl- (1 → 3) -O- α-L-rhamnopyranosyl- (1 → 6) -O- β-D-glucopyranoside and quercetin 3-O- [3-0 " O- [3-O- (E) -p-coumaroyl] [[alpha] -L-laminopyranosyl- (1-6) -O- [beta] -D- glucopyranoside] L-rhamnopyranosyl- (1 → 6) -O- β-D-glucopyranoside] was isolated and it was confirmed by ¹ H, ¹³ C-NMR, ultraviolet spectroscopy and ESI- In the case of ¹ H and ¹³ C nuclear magnetic resonance (NMR), methanol-d3 was used as a solvent, and the apparatus Was used with a Bruker Advance DPX-500 (BRUKER, USA) Water MS spectra were analyzed using a 6200 Series Accurate-Mass Time-of-Flight (TOF) LC / MS (Agilent, US).

As a result of the analysis, each of the above-mentioned compounds was found to be a novel compound not known in the prior art and having a molecular weight of 918.2430 of C ₄₂ H ₄₆ O ₂₃ , quercetin 3-O- [3-O "- (E) D-glucopyranosyl- (1 → 3) -O- α-L-laminopyranosyl- (1 → 6) -O- β-D-glucopyranoside] and a molecular weight of C ₃₆ H ₃₆ O ₁₈ of 756.1902 (1 → 6) -O- [beta] -D-glucopyranoside], which is confirmed by the quercetin 3-O- [3-O "- (E) - p-coumaroyl] [α-L-rhamnopyranosyl- .

[Beta] -D-glucopyranosyl- (1 → 3) -O- alpha -L-raminopyranosyl- (1 → 6) -quinoline- ) -O- [beta] -D-glucopyranoside] and the NMR data are as follows.

Position ¹³ C-NMR ¹ H-NMR 2 159.29 3 135.58 4 179.33 5 163.02 6 99.98 6.21 (H6, brs) 7 166.03 8 94.95 6.41 (H8, brs) 9 158.58 10 105.6 One' 123.06 2' 117.79 7.68 (H2 ', m) 3 ' 145.86 4' 149.82 5 ' 116.13 6.86 (H5 ', d, J = 8.3 Hz) 6 ' 123.48 7.62 (1H, dd, J = 8.3, 1.3 Hz) p-coumaric acid One''' 127.3 2 '' ', 6' '' 131.18 7.48 (H2 H " / H6 ", d, J = 7.8 Hz) 3 '' ', 5' '' 116.83 6.81 (H3 "'/H5'", d, J = 7.8 Hz) 4''' 161.27 7 '' ' 115.45 6.42 (1H, ", d, J = 15.4 Hz) 8''' 146.71 7.68 (H, ' ", m) C = O 168.95 Glc1 One'' 104.5 5.26 (1H, d, J = 7.7 Hz) 2'' 74.11 3.71 (H2 ', d, J = 9 Hz) 3 '' 78.93 5.11 (H3 '', t, J = 9 Hz) 4'' 69.43 3.54 (H4 ', dd, J = 9.8, 9.3 Hz) 5 '' 77.54 3.40 (H5 ' ', m) 6 '' 68.43 3.80 (H6 ', brd, J = 10.4 Hz) 3.49 Rha One'''' 102.33 4.57 (H1 " ', brs) 2'''' 70.89 3.38 (H2 H ", m) 3 '' '' 83.06 3.63 (H3 ", dd, J = 8.9, 2.2 Hz) 4'''' 72.6 3.46 (H 4 '' '', m) 5 '' '' 69.76 3.54 (H5 " ', m) 6 '' '' 17.96 1.10 (H6 "', d, J = 5.7 Hz) Glc2 One''''' 105.67 4.44 (1H, d, J = 7.5 Hz) 2''''' 75.48 3.25 (H2 " ', m) 3 '' '' ' 76.97 3.50 (H3 " ', m) 4''''' 71.28 3.96 (H 4 '' '', brs) 5 '' '' ' 77.54 3.26 (H 5 '' '', m) 6 '' '' ' 62.1 3.78-3.72 (H6 " ', m)

[Beta] -D-glucopyranosyl- (1 → 3) -O- alpha -L-raminopyranosyl- (1 → 6) -quinoline- ) -O- [beta] -D-glucopyranoside] was shown in Fig. 1, and ¹ H-NMR spectrum and ¹³ C-NMR spectrum were shown in Figs. 2 and 3, respectively. HSQC (Heteronuclear Single Quantum Coherence) spectrum is shown in FIG. 4, and HMBC (Heteronuclear Multiple-Bond Coherence) spectrum is shown in FIG.

On the other hand, it has been reported that quercetin 3-O- [3-O "- (E) - p-coumaroyl] [α-L-rhamnopyranosyl- (1 → 6) -O- 硫 -D-glucopyranoside] The formula and NMR data are as follows.

Position ¹³ C-NMR ¹ H-NMR 2 159.23 3 135.52 4 179.33 5 163.02 6 99.96 6.21 (H6, brs) 7 166.04 8 94.85 6.40 (H8, brs) 9 158.52 10 105.64 One' 123.06 2' 117.68 7.67 (H2 ', d, J = 8.7 Hz) 3 ' 145.88 4' 149.86 5 ' 116.11 6.89 (H < 5 >', d, J = 8.4 Hz) 6 ' 123.52 7.63 (H6 ', dd, J = 8.4, 1.7 Hz) p-coumaric acid One''' 127.29 2 '' ', 6' '' 131.17 7.48 (H2 " / H6 ", d, J = 8.4 Hz) 3 '' ', 5' '' 116.82 6.81 (H3 "'/H5'", d, J = 8.4 Hz) 4''' 161.26 7 '' ' 115.44 6.42 (1H, ", d, J = 15.7 Hz) 8''' 146.7 7.68 (H, '", d, J = 15.7 Hz) C = O 168.97 Glc1 One'' 101.55 5.28 (1H, d, J = 7.8 Hz) 2'' 74.14 3.71 (2 ", d, J = 9 Hz) 3 '' 73.25 5.11 (H3 '', t, J = 9.2 Hz) 4'' 70.47 3.54 (H4 ', dd, J = 9.8, 9.3 Hz) 5 '' 75.51 3.40 (H5 ' ', m) 6 '' 67.54 3.80 (H6 ', brd, J = 10.4 Hz) 3.49 Rha One'''' 101.85 4.53 (H1 " ', brs) 2'''' 71.34 3.38 (H2 H ", m) 3 '' '' 83.09 3.63 (H3 ", dd, J = 8.9, 2.2 Hz) 4'''' 72.6 3.46 (H 4 '' '', m) 5 '' '' 69.49 3.54 (H5 " ', m) 6 '' '' 18.08 1.12 (H6 "', d, J = 6.1 Hz)

The MS spectrum of quercetin 3-O- [3-O "- (E) - p-coumaroyl] [α-L-rhamnopyranosyl- (1 → 6) -O- β-D- glucopyranoside] 7 and 8 show the ¹ H-NMR spectrum and ¹³ H-NMR spectrum, respectively, and FIG. 9 shows the spectrum of the HSQC (Heteronuclear Single Quantum Coherence) -Bond Coherence) spectrum was as shown in Fig.

[Experimental Example 1] Confirmation of beta amyloid aggregation inhibitory effect

(1 → 3) -O- α-L-raminopyranosyl- (1 → 3) -O- [3-O " (1 → 6) -O-β-D-glucopyranoside] and quercetin 3-O- [3-O " -O-? - D-glucopyranoside] was confirmed by the fluorescence assay (ThioflavinT assay).

Specifically, β-amyloid (Aβ1-42, AnaSpec Inc, USA) was obtained and used at a concentration of 0.1 mg / ml and stored at -80 ° C. prior to use. (3-O- (E) -p-coumaroyl] [[beta] -D-glucopyranosyl- (1, 2-dimethylaminophenyl) (1 → 6) -O- β-D-glucopyranoside] (1 mg / ml), quercetin 3-O- [3-O "- (1? 6) -O-? -D-glucopyranoside] (1 mg / ml) was diluted and adjusted to the above concentrations. To specify the degree of inhibition of A [beta] i-42 aggregation, 50 [mu] l of 0.01 M sodium phosphate buffer solution was diluted to 10 [mu] M with each compound prepared at the above concentration, and then 40 l of 0.1 mg / ml A [beta] (Thioflavin T) was added to each well and fluorescence was measured at 37 ° C for 15 minutes at 5 minute intervals using a fluorescence spectrometer (RF-5300PC, SHIMADZU CORPORATION, Japan).

The results are shown in Table 3 and FIG. 11 below.

Increased RFU Increased RFU
(% of Pos.Cont.) Pos.Cont. 14595 100.0 New substance 31 12955 88.8 New substance 32 12148 83.2 Morin 11471 78.6 Phenol Red 13655 93.6

In the above table, RFU is the relative fluorescence unit, "Increased RFU" indicates the amount of aggregated beta amyloid, and "Increased RFU (% of Pos.Cont.)" Indicates the amount of aggregated beta amyloid compared with the positive control . "New substance 31" refers to quercetin 3-O- [3-O "- (E) -p-coumaroyl] [β-D-glucopyranosyl- (1 → 3) -O- (1 → 6) -O- β-D-glucopyranoside], and "new substance 32" represents quercetin 3-O- [3-O "- (E) ? -L-laminopyranosyl- (1? 6) -O-? -D-glucopyranoside].

3-O- [3-O "- (E) - (3-O) - (3-O) - (1 → 6) -O- β-D-glucopyranoside] and quercetin (β-D-glucopyranosyl- (1 → 3) -O- (1 → 6) -O- [beta] -D-glucopyranoside] was detected in each of the positive control group And 11.2% and 16.8%, respectively. These results indicate that the substance has beta amyloid aggregation inhibition and plaque formation inhibitory effect as good as the known inhibitors Morin (21.4%) and Phenol red (6.4%). Accordingly, the two compounds have the above-mentioned effects and can be used for prevention, treatment, and improvement of cognitive dysfunction associated with beta-amyloid aggregation. In addition, it is possible to prevent, prevent and inhibit neuronal damage or death due to beta amyloid aggregation or the like, thereby protecting nerve cells.

[Experimental Example 2] Skin cumulative stimulation experiment

(1 → 3) -O- α-L-raminopyranosyl- (1 → 3) -O- [3-O " (1 → 6) -O-β-D-glucopyranoside] and quercetin 3-O- [3-O " -O-β-D-glucopyranoside], and human repeated insult patch tests (HRIPT) were conducted to calculate the range of concentrations available for skin.

Specifically, 15 healthy adult subjects were randomly selected, and a test composition (composition for a skin including an emulsifier, a stabilizer, purified water and the like in addition to the above compound) containing 0.5 wt%, 1 wt% and 3 wt% (IQ chamber, Epitest Ltd, Finland) was dropped in a chamber (IQ chamber, Epitest Ltd, Finland), and after 24 hours from being applied to the right side of the subject, In this way, the skin reaction was checked before and after the patch every time, and the skin reaction was checked for 48 hours after the removal of the final patch, and the average response was obtained.

The results are shown in Table 4 below.

Test substance and content ±, +, or ++ Number of subjects showing reactivity (unit: person) Average reactivity 1 time Episode 2 3rd time 4 times 5 times 6 times 7 times 8 times 9 times Control group 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 New substance 31 0.5 wt% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 New substance 31
1 wt% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 New substance 31
3 wt% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 New substance 32 0.5 wt% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 New substance 32
1 wt% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 New substance 32
3 wt% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Reactivity
-: voice (no reaction)
±: Suspicious or slight erythema
+: Weak response (not accompanied by a small respiratory tract), erythema, papules
++: Severe reaction (accompanied by small respiratory tract), erythema, papule,
+++: strong reaction, algebraic reaction

Average Reaction Rate Formula

X 100] / number of examinations (9 times) = number of examinations (number of examinations = number of examinations)

If the reactivity is -, the response index is 0, if the reactivity is ±, the response index is 1. If the reactivity is +, the response index is 2. If the reactivity is ++, the response index is 4.

A safe composition is determined when the average degree of reactivity is less than 3

The skin reaction was judged according to the criteria of the International Contact Dermatitis Research Group (ICDRG). In the above table, "novel substance 31" is a quercetin 3-O- [3-O "-( E) -p-coumaroyl] [beta] -D-glucopyranosyl- (1 → 3) (1 → 6) -O- β-D-glucopyranoside], and "new substance 32" represents quercetin 3-O- [3-O "- (E) (1? 6) -O-? -D-glucopyranoside]. The term "[alpha] -L-laminopyranosyl- In other words, both of the substances showed a (-) response in the content range (±, +, ++, or +++), indicating that the substance did not accumulate in the skin, And it can be safely used.

[Experimental Example 3] Confirmation of the expression level of intracellular BDNF (brain-derived neurotrophic factor) and DNMT1 (cytosine-5-methyltransferase 1)

It was confirmed whether the new substance 31 and the novel substance 32 exerted their effects in cells as well.

Specifically, SH-SY5Y (neuroblastoma, Korean Cell Line Bank) cell line was seeded at a rate of 2 × ¹⁰ 6 cells per well in a 6-well plate (FALCON), cultured in a 5% CO ₂ incubator at 37 ° C. for 24 hours , 10 μg / ml of GCG, 10 μg of EGCG, 10 μg / ml of green tea extract (GTE), 10 μg / ml of the new substance 31, 10 μg / ml of the new substance 32, Aza-2'deoxycytidine (5-Aza, Sigma-aldrich) at 1 μM for 24 h. Then, the medium was removed and RNA was extracted using an RNA extraction kit (RNeasy mini kit, Quiagen). The extracted mRNA was quantitated using an ultraviolet detector (TECAN), and 1 μg of mRNA was synthesized as a complementary DNA using a kit (SuperScript VILO cDNA Synthesis Kit, Thermofisher Scientific). Approximately 1 μg of complementary DNA was taken and subjected to real-time quantitative chain reaction using a Taqman probe (Life technology) and a Quantitect Probe PCR Kit (Quiagen). The expression level of BDNF and DNMT1 was confirmed. The housekeeping gene, GAPDH, was used as the reference mRNA.

The expression levels of BDNF and DNMT1 are shown in Table 5 and Table 6, respectively.

Relative expression level of BDNF division % Control group (untreated group) 100 New substance 31 (10 [mu] g / ml)     123 New substance 32 (10 [mu] g / ml) 131 5-Aza-2 ' deoxycytidine 1 [mu] M 149

Relative expression level of DNMT1 division % Control group (untreated group) 100 New substance 31 (10 [mu] g / ml)     81 New substance 32 (10 [mu] g / ml) 74 5-Aza-2 ' deoxycytidine 1 [mu] M 65

Since both the novel substance 31 and the novel substance 32 lower the expression of DNMT1 and increase the expression of BDNF, the two compounds can prevent, prevent and inhibit neuronal cell injury or death, thereby contributing to nerve cell protection and neurodegenerative diseases Prevention and improvement can be promoted.

Hereinafter, a formulation example of a composition according to one aspect of the present invention will be described, but the scope of the present invention is not limited thereto.

[Formulation Example 1] Soft capsule

[Beta] -D-glucopyranosyl- (1 → 3) -O- alpha -L-raminopyranosyl- (1 → 6) -quinoline- ) -O-? - D-glucopyranoside] or quercetin 3-O- [3-O "- (E) O-beta-D-glucopyranoside], 80 to 140 mg of L-carnitine, 180 mg of soybean oil, 2 mg of palm oil, 8 mg of vegetable hydrogenated oil, 4 mg of yellow radish and 6 mg of lecithin were mixed and filled into 1 capsule according to a conventional method, A capsule was prepared.

[Formulation Example 2] Tablets

[Beta] -D-glucopyranosyl- (1 → 3) -O- alpha -L-raminopyranosyl- (1 → 6) -quinoline- ) -O-? - D-glucopyranoside] or quercetin 3-O- [3-O "- (E) O-beta-D-glucopyranoside], 200 mg of galactooligosaccharide, 60 mg of lactose and 140 mg of maltose were mixed and granulated using a fluid bed drier, and 6 mg of sugar ester was added thereto. .

[Formulation Example 3]

[Beta] -D-glucopyranosyl- (1 → 3) -O- alpha -L-raminopyranosyl- (1 → 6) -quinoline- ) -O-? - D-glucopyranoside] or quercetin 3-O- [3-O "- (E) O-beta-D-glucopyranoside], 250 mg of anhydrous crystalline glucose and 550 mg of starch were mixed and granulated into granules using a fluidized bed granulator, and filled in a vial to prepare granules.

[Formulation Example 4] Drinking agent

[Beta] -D-glucopyranosyl- (1 → 3) -O- alpha -L-raminopyranosyl- (1 → 6) -quinoline- ) -O-? - D-glucopyranoside] or quercetin 3-O- [3-O "- (E) O-beta-D-glucopyranoside], 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharide are mixed, and 300 ml of purified water is added to each bottle. And the mixture was sterilized at 130 DEG C for 4 to 5 seconds to prepare a drink.

[Formulation Example 5]

[Beta] -D-glucopyranosyl- (1 → 3) -O- alpha -L-raminopyranosyl- (1 → 6) -quinoline- ) -O-? - D-glucopyranoside] or quercetin 3-O- [3-O "- (E) O-beta -D-glucopyranoside], sterilized distilled water for injection, and pH adjuster, respectively.

 [Formulation Example 6] Health food

Healthy foods were prepared in a conventional manner according to the composition shown in Table 7 below.

ingredient content [Beta] -D-glucopyranosyl- (1 → 3) -O- alpha -L-raminopyranosyl- (1 → 6) -quinoline- ) -O-? - D-glucopyranoside] or quercetin 3-O- [3-O "- (E) O- [beta] -D-glucopyranoside]  0.5 mg Vitamin mixture Vitamin A acetate 70 [mu] g Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 [mu] g Vitamin C 10 mg Biotin 10 [mu] g Nicotinic acid amide 1.7 mg Folic acid 50 [mu] g Calcium pantothenate 0.5 mg Mineral mixture Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium monophosphate 15 mg Dicalcium phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg

Although the composition ratio of the vitamin and the mineral mixture is relatively mixed with the ingredient suitable for health food, the compounding ratio of the vitamin and the mineral mixture may be arbitrarily varied. The ingredients may be mixed according to a conventional method for producing health food, Can be used for the production of health food compositions.

[Formulation Example 7] Health drinks

ingredient content [Beta] -D-glucopyranosyl- (1 → 3) -O- alpha -L-raminopyranosyl- (1 → 6) -quinoline- ) -O-? - D-glucopyranoside] or quercetin 3-O- [3-O "- (E) O- [beta] -D-glucopyranoside]  10 mg Citric acid 1000 mg oligosaccharide 100 g Plum concentrate 2 g Taurine 1 g Purified water Balance Total volume 900 ml

The remaining components were mixed according to a conventional health drink manufacturing method by adding a remaining amount of purified water to a total volume of 900 ml as shown in Table 8, and the mixture was stirred and heated at 85 DEG C for about 1 hour, Sterilized 2 liter container, sealed sterilized, and stored in a refrigerator to prepare a health drink.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention . Accordingly, the actual scope of the disclosure will be defined by the appended claims and their equivalents.

Claims (20)

A composition for improving cognitive function lowering comprising an effective amount of a compound of the following formula 1, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, or a post-fermentation tea extract containing the same
[Chemical Formula 1]

In the general formula 1 R ₁ is _{C 15 H 9 O 7, R} 2 is H or _{C 6 H 11 O 5, R} 3 is C ₉ H ₇ O ₂ is, improved composition for cognitive decline. 2. The composition of claim 1, wherein R < ₁ >
(2)

. 2. The composition of claim 1, wherein R < ₂ >
(3)

. The composition of claim 1, wherein R ₃ is a compound of formula
[Chemical Formula 4]

. The compound of claim 1, wherein the compound is selected from the group consisting of quercetin 3-O- [3-O "- (E) -p-coumaroyl] [β-D-glucopyranosyl- (1? 6) -O-? -D-glucopyranoside] (Quercetin3-O- [3-O "- (E) -p- coumaroyl] [? - D- glucopyranosyl- ? 3) -O-? -L-rhamnopyranosyl- (1? 6) -O-? -D-glucopyranoside]. The compound of claim 1, wherein said compound is selected from the group consisting of quercetin 3-O- [3-O- (E) -p-coumaroyl] [? -L-raminopyranosyl- (1-6) -Glucopyranoside] (Quercetin 3-O- [3-O "- (E) -p-coumaroyl] [α-L-rhamnopyranosyl- (1 → 6) -O- β-D-glucopyranoside]. The composition of claim 1, wherein the extraction is extraction with at least one solvent selected from hydrothermal, C ₁ to C ₆ lower alcohols, and mixed solvents thereof. 8. The composition of claim 7, wherein the lower alcohol is ethanol. The composition of claim 1, wherein the extract is a fraction that is fractionated into ketones after extraction. 10. The composition of claim 9, wherein the ketone is acetone. The composition of claim 1, wherein the composition of Formula 1, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof is 0.00001% to 10% by weight relative to the total weight of the composition. The composition of claim 1, wherein the content of post-fermentation tea extract in the composition is from 0.1% to 90% by weight relative to the total weight of the composition. The extract of claim 1, wherein the extract comprises 0.0001 to 20% by weight of the compound of formula (I), its isomer, its pharmaceutically acceptable salt, its hydrate or solvate thereof in an amount of 0.0001 to 20% ≪ / RTI > The pharmaceutical composition according to claim 1, wherein the dose of the compound of Formula 1, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof is 0.001 mg / kg / day to 100 mg / / Day, composition. 15. The method according to any one of claims 1 to 14, wherein the cognitive decline is due to aggregation of beta amyloid, brain-derived neurotrophic factor (BDNF) Or increased expression of DNA (cytosine-5) -methyltransferase 1 (DNMT1). 15. The composition according to any one of claims 1 to 14, wherein the cognitive decline comprises at least one selected from the group consisting of memory loss, cognitive decline, discrimination decline, depression, and forgetfulness. 15. The method according to any one of claims 1 to 14, wherein the improvement is through at least one selected from the group consisting of inhibition of aggregation of beta-amyloid, degradation of aggregated beta-amyloid, enhancement of BDNF expression, and decrease of DNMT1 expression ≪ / RTI > 15. The composition according to any one of claims 1 to 14, wherein the composition is a composition for protecting a nerve cell. 19. The method of claim 18, wherein the neuronal cell protection is selected from the group consisting of agglutination of beta amyloid, brain-derived neurotrophic factor (BDNF) -methyltransferase 1) expression in a mammal. 15. The composition according to any one of claims 1 to 14, wherein the composition is a food or pharmaceutical composition.

Images